Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta‐analysis |
| |
| Authors: | Yawei Wang Fang Gao Meng Zhao Bing Li Dan Xing Jie Wang Yang Yang |
| |
| Affiliation: | 1. Department of Electromyography, Tianjin Hospital, Tianjin, China;2. Department of Gastroenterology, Tianjin Dong Li Hospital, Tianjin, China;3. Department of Laboratory Medicine, Tianjin Medical University Cancer Hospital, Tianjin, China;4. Department of Orthopedics, Tianjin Hospital, Tianjin, China |
| |
| Abstract: | Enhancer of zeste 2 (EZH2), a key component of polycomb repressive complex 2 (PRC2), was of great importance in human cancer pathogenesis. Various studies examined the relationship between EZH2 overexpression with the clinical outcome in patients with digestive cancers, but yielded conflicting results. Electronic databases updated to January 2015 were searched to find relevant studies. A meta‐analysis was conducted with eligible studies which quantitatively evaluated the relationship between EZH2 overexpression and survival of patients with digestive cancers. Survival data were aggregated and quantitatively analysed. We performed a meta‐analysis of 10 studies (n = 1461 patients) that evaluated the correlation between EZH2 overexpression and survival in patients with digestive cancers. Combined hazard ratios suggested that EZH2 overexpression was associated with poor prognosis of overall survival (HR = 1.54, 95% CI: 1.27–1.81) in patients with oesophageal cancer. In the stratified analysis, no significant risks were found among gastric cancer (HR = 0.66, 95% CI: 0.16–1.15) and colorectal cancer (HR = 0.91, 0.63–1.19), indicating that EZH2 was not an indicator of poor prognosis in gastric cancer or colorectal cancer. Enhancer of zeste 2 overexpression indicates a poor prognosis for patients with oesophageal cancer, but not among gastric cancer or colorectal cancer. |
| |
| Keywords: | enhancer of zeste homolog 2 oesophageal cancer colorectal cancer gastric cancer prognosis meta‐analysis |
|
|
